➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Colorcon
Boehringer Ingelheim
AstraZeneca
Express Scripts

Last Updated: July 24, 2021

DrugPatentWatch Database Preview

Patent: 10,004,747

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,004,747
Title:Combination therapy
Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
Inventor(s): Klein; Thomas (Radolfzell, DE), Grempler; Rolf (Birkenhard/Warthausen, DE), Mark; Michael (Biberach an der Riss, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:15/428,594
Patent Claims:see list of patent claims

Details for Patent 10,004,747

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471 002 2016-07-27 ⤷  Free Forever Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2030-05-05 RX search
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471 001 2016-07-27 ⤷  Free Forever Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2030-05-05 RX search
Eli Lilly And Co TRULICITY dulaglutide INJECTABLE;INJECTION 125469 002 2015-03-09 ⤷  Free Forever Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2030-05-05 RX search
Eli Lilly And Co TRULICITY dulaglutide INJECTABLE;INJECTION 125469 001 2015-03-09 ⤷  Free Forever Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2030-05-05 RX search
Glaxosmithkline Llc TANZEUM albiglutide INJECTABLE;INJECTION 125431 001 2014-04-15 ⤷  Free Forever Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2030-05-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,004,747

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2011138421 ⤷  Free Forever Trial
United States of America 2013281373 ⤷  Free Forever Trial
United States of America 2016038500 ⤷  Free Forever Trial
United States of America 2017151249 ⤷  Free Forever Trial
United States of America 9186392 ⤷  Free Forever Trial
United States of America 9603851 ⤷  Free Forever Trial
New Zealand 602921 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
McKesson
Colorcon
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.